psilocybin has been researched along with Depression, Endogenous in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Leger, RF; Unterwald, EM | 1 |
| Castle, DJ; Liknaitzky, P; Meikle, SE; Murray, G; Ross, M; Rossell, SL; Strauss, N; Thomas, N; Williams, M | 1 |
| Mathuru, AS; Vitkauskas, M | 1 |
| Baker, G; Dos Santos, RG; Dursun, S; Hallak, JE | 1 |
| Strauss, N | 1 |
| Alcázar-Córcoles, MÁ; Bouso, JC; Dos Santos, RG; Hallak, JEC | 1 |
| Andreassen, OA; Kvam, TM; Stewart, LH | 1 |
| Ardissino, M; John, C; Muttoni, S | 1 |
| McCorvy, JD; Olsen, RH; Roth, BL | 1 |
| Young, SN | 1 |
| JAROS, O; KOVARIK, J; SERCL, M | 1 |
| CANCRINI, L; D AGOSTINO, E; REDA, GC; VELLA, G | 1 |
| Abadie, P; Dollfus, S; Espiard, ML; Halbecq, I; Lecardeur, L | 1 |
7 review(s) available for psilocybin and Depression, Endogenous
| Article | Year |
|---|---|
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Topics: Affect; Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2022 |
Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.
Topics: Brain Diseases; Comorbidity; Depression; Depressive Disorder; Habenula; Hallucinogens; Humans; Psilocybin; Serotonergic Neurons | 2020 |
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Topics: Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Randomized Controlled Trials as Topic; Serotonin Agents; Substance-Related Disorders | 2018 |
Psychedelic drugs in the treatment of anxiety, depression and addiction.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Substance-Related Disorders | 2018 |
Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2019 |
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Topics: Affect; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety Disorders; Attitude; Behavior; Botulinum Toxins; Depressive Disorder; Facial Expression; Hallucinogens; Humans; Ketamine; Placebo Effect; Psilocybin; Treatment Outcome | 2013 |
[CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN].
Topics: Antisocial Personality Disorder; Asthenia; Blood Pressure; Consciousness; Depression; Depressive Disorder; Electroencephalography; Hallucinations; Hallucinogens; Hearing Disorders; Indoles; Mental Disorders; Mental Processes; Movement Disorders; Nausea; Pharmacology; Psilocybin; Psychopathology; Salivary Glands; Sweating; Toxicology; Vestibule, Labyrinth; Visual Perception | 1964 |
6 other study(ies) available for psilocybin and Depression, Endogenous
| Article | Year |
|---|---|
Psilocybin-assisted therapy for depression: How do we advance the field?
Topics: Depressive Disorder; Hallucinogens; Humans; Psilocybin; Psychotherapy; Randomized Controlled Trials as Topic | 2020 |
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Evaluation, Preclinical; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Psilocybin; Serotonin 5-HT2 Receptor Agonists | 2021 |
Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.
Topics: Anxiety Disorders; Depressive Disorder; Euthanasia; Hallucinogens; Humans; Psilocybin; Randomized Controlled Trials as Topic | 2017 |
Psilocybin for depression and anxiety associated with life-threatening illnesses.
Topics: Anxiety; Depression; Depressive Disorder; Hallucinogens; Humans; Psilocybin | 2016 |
[Clinical experiences with psilocybin (CY 39 Sandoz)].
Topics: Depression; Depressive Disorder; Indoles; Neurotic Disorders; Psilocybin | 1961 |
Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depressive Disorder; Diagnosis, Differential; Hallucinogens; Humans; Male; Marijuana Smoking; Perceptual Disorders; Psilocybin; Psychiatric Status Rating Scales; Recurrence; Risperidone; Sertraline; Social Behavior Disorders; Time Factors | 2005 |